New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ChromaDex reports financial results for Q4 and year ended 2010

ChromaDex Corporation announced financial results of its fiscal year with revenues of approximately $7.6 million ending January 1, 2011.

ChromaDex Corporation, (OTC Bulletin Board: CDXC) an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, announced financial results of its Fiscal Year ending January 1, 2011. On a reported basis and calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced total revenues of approximately $7.6 million and a net loss attributable to common stockholders of $0.04 per share for the one year period ended January 1, 2011. As of January 1, 2011, cash, cash equivalents, and marketable securities totaled over $2.2 million.

"2010 was a landmark year for ChromaDex as we launched our new pterostilbene ingredient, pTeroPure, into the market in September and strengthened our senior management team in several ways, including the hiring of Bill Spengler as President," said Frank Jaksch, CEO and co-founder of ChromaDex. "Going into 2011, we are now poised to leverage our unique product and service offerings and at the same time capture rapidly growing revenues related to pTeroPure and other novel ingredients. We expect this combination to further solidify ChromaDex as a leader in the natural products industry."

Additional Financial Results & Notes

On a reported basis, ChromaDex recorded revenue during 2010 of $7,566,370 as compared to $5,777,865 in 2009, representing year on year growth in excess of 31%. The net loss attributable to common stockholders for the year January 1, 2011, was $2,051,676 as compared to a net loss of $907,568 in 2009. The increased net loss in 2010 as compared to the same period in 2009 was largely due to share-based compensation expense related to the stock options that were granted following the May 20, 2010 Private Placement. When the net loss is adjusted to exclude the effects of non-cash charges associated with share-based compensation expense, a "non-GAAP" presentation, the net loss for 2010 is $789,605 and the loss per share for 2010 is $0.02.

About ChromaDex

ChromaDex is a leader in the development of phytochemical and botanical reference standards, as well as analytical tools and services to meet product regulatory, quality, efficacy and safety standards. ChromaDex discovers, develops and markets novel, natural ingredients that fill unmet needs in the dietary supplement, food and beverage, cosmetic or pharmaceutical markets. Through a combination of licensed technology and its own R&D, ChromaDex utilizes plants and natural products to develop innovative ingredients. The company has an impressive pipeline of new ingredients, including its pTeroPure™ pterostilbene on which it has worldwide, exclusive patent rights. ChromaDex has initiated a clinical study on this new product, pTeroPure™ pterostilbene ( For more information, visit or follow ChromaDex on Twitter @ChromaDex.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.